RAPT Therapeutics, Inc. - FORM 10-K - EX-23.1 - March 11, 2021

Attached files

file filename
EX-32.2 - EX-32.2 - RAPT Therapeutics, Inc.rapt-ex322_11.htm
EX-32.1 - EX-32.1 - RAPT Therapeutics, Inc.rapt-ex321_7.htm
EX-31.2 - EX-31.2 - RAPT Therapeutics, Inc.rapt-ex312_12.htm
EX-31.1 - EX-31.1 - RAPT Therapeutics, Inc.rapt-ex311_10.htm
10-K - 10-K - RAPT Therapeutics, Inc.rapt-10k_20201231.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

 

(1)

Registration Statement (Form S-8 No. 333-234448) pertaining to the 2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan of RAPT Therapeutics, Inc.,

 

(2)

Registration Statement (Form S-8 No. 333-237487) pertaining to the 2019 Equity Incentive Plan of RAPT Therapeutics, Inc., and

 

(3)

Registration Statement (Form S-3 No. 333-249848) of RAPT Therapeutics, Inc.;

of our report dated March 11, 2021, with respect to the consolidated financial statements of RAPT Therapeutics, Inc. included in this Annual Report (Form 10-K) of RAPT Therapeutics, Inc. for the year ended December 31, 2020.

                                                                                                                                                /s/ Ernst & Young LLP

 

Redwood City, California

March 11, 2021

 

RAPT Therapeutics, Inc. Reports